York-based Aptamer Group plc has announced a second phase of research with Oxfordshire-based Neuro-Bio to develop tests to early detect Alzheimer’s disease.
Steve Hull, Chairman of Aptamer Group, said: “We are very pleased to continue our exciting relationship with Neuro-Bio to deliver the specific Optimer binders needed to enable this revolutionary diagnostic for this devastating disease.
"It is great to work with such enthusiastic partners that understand our Optimer technology’s benefits and are actively seeking solutions to overcome the industry’s problems with antibodies.”
Baroness Susan Greenfield, CEO of Neuro-Bio, said: “At Neuro-Bio we’re thrilled at entering this next phase of development with Aptamer Group.
"The first phase proved productive and very promising. Now, this next stage takes us closer to realising a highly novel and much needed technology for detecting neurodegenerative diseases at a very early stage.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here